



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES

Earl Ray Tomblin
Governor

Bureau for Medical Services
Pharmacy Services
350 Capitol Street – Room 251
Charleston, West Virginia 25301-3706
Telephone: (304) 558-1700 Fax: (304) 558-1542

Karen L. Bowling
Cabinet Secretary

Pharmaceutical and Therapeutics Committee
January 28, 2015

Location: Diamond, Rooms B10 and B11
Time: 2:00 PM – 5:00 PM
Charleston, WV 25301
(304) 558-1700

MINUTES

Members Present:

Jeffrey V. Ashley, M.D.
Elizabeth Baldwin, RN, MSN, PNP, APRN-BC (on phone)
Scott Brown, R.Ph.
Bradley Henry, M.D., Vice Chairman
Tom Kines, R.Ph.
Steve Neal, Pharm.D.
Robert Stanton, Pharm.D., Chairman

Members Not Present:

Rodney L. Fink, D.O.
Hani Nazha, M.D.

DHHR/BMS Staff Present:

Vicki Cunningham, R.Ph., Pharmacy Director
Brian Thompson, MS, Pharm.D., DUR Coordinator
William Hopkins, Pharmacy Operations Manager
Gail Goodnight, R.Ph., Drug Rebate Program Director
Richard D. Sorvig, Administrative Assistant

Contract Staff/Magellan Medicaid Administration (MMA) Staff Present:

Nina Bandali, Pharm.D.
Giovannino Perri, M.D.

Other Contract Staff/State Staff Present:

Eric Sears, R.Ph., Molina Medicaid Solutions
Steve Small, R.Ph., MS, Director, Rational Drug Therapy Program

I. Call to Order

Dr. Robert Stanton, Chairman, called the meeting to order at 2:00PM.

II. Welcome and Introductions

Dr. Stanton welcomed the newest member of the P&T Committee, Dr. Steve Neal. All parties seated at the table and on the phone introduced themselves.

III. Housekeeping Items/Updates

A. Approval of the October 22, 2014 Minutes

Dr. Stanton asked for approval of the minutes from the October 22, 2014 P&T meeting. A motion was made and seconded; the motion carried to approve the minutes as submitted.

B. PDL Compliance/Generic Percent Report Updates

Dr. Nina Bandali reported the overall PDL compliance for Q3 2014 was 96.8% and the generic utilization rate for Q3 2014 was 83.1%.

IV. Public Comments

Ms. Cunningham thanked the staff of BMS for taking care of the last P&T meeting in October during her absence. She explained the public comment process, including the time limit of three minutes per product for each speaker. The following people spoke:

Rafael Muniz, Mylan, spoke in favor of Epipen.

Timothy Hampton, Kaleo, spoke in favor of Evzio.

Paul Miner, Gilead, spoke in favor of Harvoni.

V. Executive session

The motion was made and seconded to adjourn to executive session for confidential pricing discussion. A vote was taken and the motion was approved at 2:15PM. The meeting resumed at 3:10M.

VI. Old Business

None

VII. New Business

A. New Generics

Dr. Bandali stated that the following generics are non-preferred. The motion to approve the recommendations as presented was made and seconded. A vote was taken and the motion was approved.

entecavir (generic for Baraclude)

amlodipine/valsartan (generic for Exforge)

olopatadine (generic for Patanase)

B. Re-Review

1. Epinephrine, Self-Injected

Dr. Bandali recapped the decision to table the recommendation for the class of Epinephrine, Self-injected during the October P&T meeting. She stated the recommendation is the same to move AuviQ and epinephrine to preferred and move EpiPen and EpiPen Jr. to nonpreferred. Dr. Bandali commented on the overall savings for the entire class. The figure was not meant as a representation of a comparison between any two products. A motion was made to accept the recommendations as presented. A vote was taken and the motion was approved.

EPINEPHRINE, SELF-INJECTED

AUVI-Q (epinephrine)
epinephrine

ADRENALIN (epinephrine)
EPIPEN (epinephrine)
EPIPEN JR (epinephrine)

C. New Drug Reviews

1. Neuac

MMA recommended that Neuac be made nonpreferred in the Acne Agents, Topical category. A motion was made to accept the recommendation as presented. A vote was taken and the motion was approved.

ACNE AGENTS, TOPICAL^{AP}

COMBINATION AGENTS

erythromycin/benzoyl peroxide

ACANYA (clindamycin phosphate/benzoyl peroxide)
AVAR/-E/LS (sulfur/sulfacetamide)
BENZAACLIN GEL (benzoyl peroxide/ clindamycin)
BENZAMYCIN PAK (benzoyl peroxide/
erythromycin)
benzoyl peroxide/clindamycin gel
benzoyl peroxide/urea
CERISA (sulfacetamide sodium/sulfur)
CLARIFOAM EF (sulfacetamide/sulfur)
CLENIA (sulfacetamide sodium/sulfur)
DUAC (benzoyl peroxide/clindamycin)
EPIDUO (adapalene/benzoyl peroxide)*
INOVA 4/1, 5/2 (benzoyl peroxide/salicylic acid)
NEUAC (clindamycin phosphate/benzoyl peroxide)
NUOX (benzoyl peroxide/sulfur)
PRASCION (sulfacetamide sodium/sulfur)
SE 10-5 SS (sulfacetamide/sulfur)
SSS 10-4 (sulfacetamide /sulfur)
SSS 10-5 foam (sulfacetamide /sulfur)
sulfacetamide sodium/sulfur cloths, lotion, pads,
suspension
sulfacetamide/sulfur wash/cleanser
sulfacetamide/sulfur wash kit
sulfacetamide sodium/sulfur/ urea
SUMADAN/XLT (sulfacetamide/sulfur)
SUMAXIN/TS (sulfacetamide sodium/sulfur)
VELTIN (clindamycin/tretinoin)*
ZIANA (clindamycin/tretinoin)*

2. Vogelxo

MMA recommended that Vogelxo be made nonpreferred in the Androgenic Agents category. A motion was made to accept the recommendation as presented. A vote was taken and the motion was approved.

ANDROGENIC AGENTS

ANDRODERM (testosterone)	AXIRON (testosterone)
ANDROGEL (testosterone)	FORTESTA (testosterone)
TESTIM (testosterone)	testosterone gel
	VOGELXO (testosterone)

3. Qudexy XR

MMA recommended that Qudexy XR be made nonpreferred in the Anticonvulsants category. A motion was made to accept the recommendation as presented. A vote was taken and the motion was approved.

ANTICONVULSANTS

carbamazepine	APTIOM (eslicarbazepine)
carbamazepine ER	BANZEL(rufinamide)
carbamazepine XR	DEPAKENE (valproic acid)
CARBATROL (carbamazepine)	DEPAKOTE (divalproex)
DEPAKOTE SPRINKLE (divalproex)	DEPAKOTE ER (divalproex)
divalproex	divalproex sprinkle
divalproex ER	EQUETRO (carbamazepine)
EPITOL (carbamazepine)	FANATREX SUSPENSION (gabapentin)
FELBATOL (felbamate)	felbamate
GABITRIL (tiagabine)	FYCOMPA (perampanel)
lamotrigine	KEPPRA (levetiracetam)
levetiracetam	KEPPRA XR (levetiracetam)
oxcarbazepine tablets	LAMICTAL (lamotrigine)
TEGRETOL XR (carbamazepine)	LAMICTAL CHEWABLE (lamotrigine)
topiramate	LAMICTAL ODT (lamotrigine)
TRILEPTAL SUSPENSION (oxcarbazepine)	LAMICTAL XR (lamotrigine)
valproic acid	lamotrigine dose pack
VIMPAT(lacosamide) ^{AP*}	lamotrigine ER
zonisamide	levetiracetam ER
	ONFI (clobazam) **
	ONFI SUSPENSION (clobazam) **
	oxcarbazepine suspension
	OXTELLAR XR (oxcarbazepine)
	POTIGA (ezogabine)
	QUDEXY XR (topiramate ER)
	SABRIL (vigabatrin)
	STAVZOR (valproic acid)
	TEGRETOL (carbamazepine)
	tiagabine
	TOPAMAX (topiramate)
	topiramate ER
	TRILEPTAL TABLETS (oxcarbazepine)
	TROKENDI XR (topiramate)
	ZONEGRAN (zonisamide)

4. Jublia

MMA recommended that Jublia be made nonpreferred in the Antifungals, Topical category. A motion was made to accept the recommendation as presented. A vote was taken and the motion was approved.

ANTIFUNGALS, TOPICAL^{AP}	
econazole ketoconazole cream, shampoo MENTAX (butenafine) miconazole (OTC) nystatin	CICLODAN (ciclopirox) ciclopirox ERTACZO (sertaconazole) EXELDERM (sulconazole) EXTINA (ketoconazole) JUBLIA (efinaconazole) ketoconazole foam KETODAN (ketoconazole) LOPROX (ciclopirox) LUZU (luliconazole) MYCOSTATIN (nystatin) NAFTIN CREAM (naftifine) NAFTIN GEL (naftifine) NIZORAL (ketoconazole) OXISTAT (oxiconazole)* PEDIPIROX-4 (ciclopirox) PENLAC (ciclopirox) VUSION (miconazole/petrolatum/zinc oxide) XOLEGEL (ketoconazole)

5. Sitavig

MMA recommended that Sitavig be made nonpreferred in the Antivirals, Oral category. A motion was made to accept the recommendation as presented. A vote was taken and the motion was approved.

ANTIVIRALS, ORAL	
ANTI HERPES	
acyclovir valacyclovir	famciclovir FAMVIR (famciclovir) SITAVIG (acyclovir) VALTREX ZOVIRAX (acyclovir)

6. Hemangeol

MMA recommended that Hemangeol be made nonpreferred in the Beta Blockers category. A motion was made to accept the recommendation as presented. A vote was taken and the motion was approved.

BETA BLOCKERS^{AP}	
BETA BLOCKERS	
acebutolol atenolol betaxolol bisoprolol metoprolol metoprolol ER nadolol pindolol	BETAPACE (sotalol) BYSTOLIC (nebivolol) CORGARD (nadolol) HEMANGEOL (propranolol) INDERAL LA (propranolol) INDERAL XL (propranolol) INNOPRAN XL (propranolol) KERLONE (betaxolol)

propranolol propranolol ER sotalol timolol	LEVATOL (penbutolol) LOPRESSOR (metoprolol) SECTRAL (acebutolol) TENORMIN (atenolol) TOPROL XL (metoprolol) ZEBETA (bisoprolol)
---	--

7. Harvoni

MMA recommended that Harvoni be made preferred in the Hepatitis C Treatments category. A member expressed his disapproval of Gilead and their unwillingness to work with Medicaid until competition arose and a Senate inquiry opened up on Gilead pricing. He stressed that he is looking forward to receiving competitive pricing on Abbvie's Hepatitis C product. Dr. Stanton stated that both Harvoni and Viekira will be reviewed during the April P&T meeting. A motion was made to accept the recommendation as presented. A vote was taken and the motion was approved with one opposed.

HEPATITIS C TREATMENTS

HARVONI (ledipasvir/sofosbuvir)* PEGASYS (pegylated interferon) PEG-INTRON (pegylated interferon) RIBASPHERE 200mg ribavirin	COPEGUS (ribavirin) INFERGEN (consensus interferon) OLYSIO (simeprevir)* REBETOL (ribavirin) RIBAPAK (ribavirin) RIBASPHERE 400mg, 600mg (ribavirin) ribavirin dose pack SOVALDI (sofosbuvir)* VICTRELIS (boceprevir)*
--	--

8. Tanzeum

MMA recommended that Tanzeum be made nonpreferred in the Hypoglycemics, Incretin Mimetics/Enhancers category. A motion was made to accept the recommendation as presented. A vote was taken and the motion was approved.

HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS INJECTABLE

BYETTA (exenatide) ^{AP} VICTOZA (liraglutide) ^{AP}	BYDUREON (exenatide)* TANZEUM (albiglutide) SYMLIN (pramlintide)**
---	--

9. Evzio

MMA recommended that Evzio be made nonpreferred in the Opiate Dependence Treatments category. A motion was made to accept the recommendation as presented. A vote was taken and the motion was approved.

OPIATE DEPENDENCE TREATMENTS

SUBOXONE FILM (buprenorphine/naloxone) ^{CL} VIVITROL (naltrexone) ^{CL} naloxone	EVZIO (naloxone) SUBOXONE TABLETS (buprenorphine/naloxone) buprenorphine/naloxone tablets ZUBSOLV (buprenorphine/naloxone)
---	---

10. Auryxia

MMA recommended that Auryxia be made nonpreferred in the Phosphate Binders category. A motion was made to accept the recommendation as presented. A vote was taken and the motion was approved.

PHOSPHATE BINDERS ^{AP}	
calcium acetate MAGNEBIND RX (calcium carbonate, folic acid, magnesium carbonate) PHOSLYRA (calcium acetate) RENAGEL (sevelamer)	AURYXIA (ferric citrate) ELIPHOS (calcium acetate) FOSRENOL (lanthanum) PHOSLO (calcium acetate) RENVELA (sevelamer carbonate) sevelamer carbonate VELPHORO (sucroferric oxyhydroxide)

11. Zontivity

MMA recommended that Zontivity be made nonpreferred in the Platelet Aggregation Inhibitors category. A motion was made to accept the recommendation as presented. A vote was taken and the motion was approved.

PLATELET AGGREGATION INHIBITORS	
AGGRENOX (dipyridamole/ASA) BRILINTA (ticagrelor) clopidogrel EFFIENT (prasugrel)	dipyridamole PERSANTINE (dipyridamole) PLAVIX (clopidogrel) TICLID (ticlopidine) ticlopidine ZONTIVITY (vorapaxar)

12. Clodan Kit

MMA recommended that Clodan Kit be made nonpreferred in the Steroids, Topical category. A motion was made to accept the recommendation as presented. A vote was taken and the motion was approved.

STEROIDS, TOPICAL	
VERY HIGH & HIGH POTENCY	
betamethasone dipropionate cream, lotion betamethasone valerate cream clobetasol propionate cream/gel/ointment/solution clobetasol emollient fluocinonide cream, gel, solution fluocinonide/emollient halobetasol propionate triamcinolone acetonide cream, ointment	amcinonide APEXICON (diflorasone diacetate) APEXICON E (diflorasone diacetate) betamethasone dipropionate gel, lotion, ointment betamethasone valerate lotion, ointment, clobetasol lotion, shampoo clobetasol propionate foam CLOBEX (clobetasol propionate) CLODAN (clobetasol propionate) CORMAX (clobetasol propionate) desoximetasone cream/gel/ointment diflorasone diacetate DIPROLENE (betamethasone dipropionate/propylene glycol) DIPROLENE AF (betamethasone dipropionate/propylene glycol) DIPROSONE (betamethasone dipropionate)

	fluocinonide ointment halcinonide HALAC (halobetasol propionate) HALOG (halcinonide) HALONATE (halobetasol propionate) KENALOG (triamcinolone acetone) LIDEX (fluocinonide) LIDEX-E (fluocinonide) OLUX (clobetasol propionate) OLUX-E (clobetasol propionate/emollient) PSORCON (diflorasone diacetate) TEMOVATE (clobetasol propionate) TEMOVATE-E (clobetasol propionate/emollient) TOPICORT CREAM, GEL, OINTMENT (desoximetasone) TOPICORT SPRAY (desoximetasone) triamcinolone acetone lotion ULTRAVATE (halobetasol propionate) ULTRAVATE PAC cream ULTRAVATE X (halobetasol propionate / lactic acid) VANOS (fluocinonide)
--	---

VIII. Next Meeting

The next P&T meeting is scheduled for April 29, 2015 at 2PM at in the Bureau for Medical Services' offices, Diamond Building, 350 Capitol Street, Charleston, WV.

IX. Other Business

Dr. Bandali stated that after review of new financial information regarding the Antibiotics, Inhaled category, MMA recommends that Tobi be moved to nonpreferred and the authorized generic of Tobi be moved to preferred. A motion was made to accept the recommendation as presented. A vote was taken and the motion was approved.

X. Adjournment

The meeting was adjourned at 3:20PM.